ライフサイエンスコーパス: liver transplant

1 ned virologic response after receiving their liver transplant.

2 ohol abstinence is typically required before liver transplant.

3 y and QoL in patients with ESLD referred for liver transplant.

4 that accurately predict renal recovery post liver transplant.

5 omes are excellent and comparable to 1-stage liver transplant.

6 y those ineligible for surgical resection or liver transplant.

7 was 70% for LDLT and 64% for deceased donor liver transplant.

8 e care surgery but has not been evaluated in liver transplant.

9 points to increase likelihood of receiving a liver transplant.

10 e waitlist death or equalize opportunity for liver transplant.

11 lity at 5 years if patients do not receive a liver transplant.

12 TD liver disease, which is only treatable by liver transplant.

13 therapy in HIV-infected patients undergoing liver transplant.

14 nation, medications chosen, and referral for liver transplant.

15 ic year [95% CI, 1.02-1.04; P < .001]) after liver transplant.

16 or clinicians who care for patients awaiting liver transplant.

17 d 2 generics in individuals with a kidney or liver transplant.

18 ated with 21-day mortality in the absence of liver transplant.

19 this approach to HCV therapy before or after liver transplant.

20 relate with survival among patients awaiting liver transplant.

21 Liver transplant.

22 ed to circulate in the blood, even after the liver transplant.

23 ls with a kidney transplant and those with a liver transplant.

24 during inpatient evaluation and care before liver transplant.

25 (9.3%) patients died and 34 (1.2%) received liver transplants.

26 flammatory diseases create the need for most liver transplants.

27 the study participants, 594 had living donor liver transplants.

28 ant recipient viral replication in kidney or liver transplants.

29 During the study period, 147 liver transplants (0.17%) were to treat BSLT.

30 segmental transplants, 47 were living donor liver transplants: 13 grafts (27.7%) were right lobes, 2

31 (48.3% vs 21.9%; P < .001), including prior liver transplant (29.3% vs 8.9%; P < .001); greater oper

32 ere acute procedural success and survival to liver transplant (3 months after PCI).

33 Of 65,206 first liver transplants, 3549 were listed for simultaneous kid

34 idney transplant saved 1,372,969 life-years; liver transplant, 465,296 life-years; heart transplant,

35 s divided for 2 adults (adult-to-adult split-liver transplant, AASLT) compared with recipients of a w

36 o advance the science and quality control of liver transplant activities in Latin America.

37 , 226 LDLTs were done in the region (8.5% of liver transplant activities).

38 s were responsible for 30% of deceased donor liver transplant activity in 2015; Austria only occasion

39 The liver transplant allocation system has evolved to a rank

40 To reduce the geographic heterogeneity in liver transplant allocation, the United Network of Organ

41 g numbers of procedures and life years after liver transplant alone (LTA) or SLK transplant.

42 The OPOs with increased competition in liver transplant also were noted to have a higher donor

43 omparing outcomes of LDLT and deceased donor liver transplant and associated risks.

44 The probability of liver transplant and death on the waiting list in the Un

45 key role in the induction of tolerance post-liver transplant and examine potential mechanisms by whi

46 Deferring HCV treatment until after liver transplant and maintaining access to the expanded

47 highlights ongoing disparities in access to liver transplant and may assist providers in understandi

48 unteers to individuals receiving a kidney or liver transplant and provides evidence that generic prod

49 Endpoints were patient survival +/- liver transplant and/or recovery of liver function.

50 eadmission varies by organ type, (highest in liver transplants and lowest in kidney transplants).

51 lular carcinoma, liver transplantation, post-liver transplant, and death).

52 r of deceased donor kidney transplants, most liver transplants, and all pancreas transplants.

53 ensated cirrhosis, hepatocellular carcinoma, liver transplants, and mortality from 2015 to 2040.

54 nt; 54 (16.4%), lung transplant; 34 (10.3%), liver transplant; and 6 (1.8%), mixed-organ transplant.

55 g that patients who are urgently requiring a liver transplant are prioritized.

56 In the United States, HIV-to-HIV kidney and liver transplants are currently permitted only under a r

57 ant Recipients who received a first isolated liver transplant at 40 years or younger (1988-2013) and

58 retrospective analysis of adults undergoing liver transplant at a large transplant center from Febru

59 identified 2330 children undergoing primary liver transplants at 21 centers.

60 nd/or malignancy who underwent primary whole-liver transplant between 2004 and 2014 at University Hos

61 n (<18 years of age) who underwent a primary liver transplant between March 2000 and January 2015.

62 base search of explant histology analysis of liver transplants between April 1993 and November 2013.

63 from the UK Transplant Registry on all 7929 liver transplants between January 2000 and December 2014

64 to discontinuation of therapy more often in liver transplant candidates and recipients (OR, 10.48; P

65 A significant proportion of liver transplant candidates and recipients do not tolera

66 In all, 78,595 adult liver transplant candidates between January 2005 and Dec

67 Among pediatric liver transplant candidates in the US, children who died

68 Levofloxacin prophylaxis of tuberculosis in liver transplant candidates is associated with a high in

69 population, the optimal management of obese liver transplant candidates remains undefined.

70 xclusion and may be cautiously undertaken in liver transplant candidates who are otherwise deemed cli

71 Liver transplant candidates will be older, more likely t

72 Liver transplant candidates with advanced renal dysfunct

73 The selection of liver transplant candidates with hepatocellular carcinom

74 The current system granting liver transplant candidates with hepatocellular carcinom

75 Liver transplant candidates with MELD exceptions have su

76 renal biopsies in a cohort of 59 consecutive liver transplant candidates with renal impairment of unc

77 Among 3852 pediatric liver transplant candidates, children who died or were d

78 and may be helpful in kidney allocation for liver transplant candidates.

79 e associated with increased risk of death in liver transplant candidates.

80 tion of red cell parameters and mortality in liver transplant candidates.

81 c steatohepatitis 3.0 versus 4.0, P < 0.001; liver transplant care 2.1 versus 3.4, P < 0.001).

82 tion (SLT) in a combined pediatric and adult liver transplant center.

83 residing more than 30 miles from specialized liver transplant centers (LTC).

84 ted, coupled with variation between the 7 UK liver transplant centers in risk appetite.

85 Thirty-eight liver transplant centers served a population of about 13

86 Liver transplant combined with chemotherapy is an excell

87 The liver transplant community in the region should push hea

88 ith DCDD from the Improving DCDD Outcomes in Liver Transplant consortium demonstrates significant dif

89 s been a notable reduction in the quality of livers transplanted, coupled with variation between the

90 Fifty-four patients who received a first liver transplant (D75 group) from 2001 to 2011 were incl

91 Liver transplant data from the Austin Hospital, Melbourn

92 variables were retrieved from the hospital's liver transplant database.

93 dict graft failure or primary nonfunction at liver transplant decision time assists utilization of sc

94 In ESLD patient referred for liver transplant, diminished QoL appears to be significa

95 adults aged 18 years or older waitlisted for liver transplant, examined on 24 days at least 30 days a

96 The recent US liver transplant experience demonstrates comparable pati

97 imary study end point was survival without a liver transplant for 1 year after the procedure.

98 A 57-year-old male patient received a liver transplant for alcoholic cirrhosis and, 6 years la

99 He subsequently underwent an orthotopic liver transplant for definitive treatment of homozygous

100 disease clinically considered for orthotopic liver transplant for different indications were enrolled

101 40 patients younger than 18 years underwent liver transplant for treatment of HBL (n = 30) or HCC (n

102 Patients receiving liver transplants for ALD or NAFLD have similar survival

103 ges of patients on the waitlist or receiving liver transplants for NASH or ALD are increasing, despit

104 tem but will increase the cost of performing liver transplants for some transplant centers.

105 e-control study of adults undergoing primary liver transplant from 2009 to 2011 was conducted.

106 hepatocellular carcinoma from 9.1% to 4.0%, liver transplants from 4.5% to 1.2%, and liver-related d

107 of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide in

108 rus (HCV) remains the leading indication for liver transplant in much of the world and has traditiona

109 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 through 2012 using

110 Forty-three patients underwent liver transplant, including 17 patients in Group 1.

111 Of livers transplanted into children, 47% were immediately

112 with hepatocellular carcinoma, will require liver transplant irrespective of their MELD meaning that

113 Invasive fungal infection (IFI) following liver transplant is associated with significant morbidit

114 l vein (PV) complications after living donor liver transplant (LDLT) have been a major concern in ped

115 ge hospital days of a pediatric living donor liver transplant (LDLT) recipient was 65.48+/-28.7, and

116 all adults (n = 1286) who underwent primary liver transplant (LT) 2000-2008 in our center.

117 virus (HCV) treatment paradigm for both pre-liver transplant (LT) and post-LT patients.

118 Liver transplant (LT) candidates today are older, have g

119 liver transplantation (BDLT) across 5 French liver transplant (LT) centers.

120 d by Karnofsky Performance Status (KPS), and liver transplant (LT) costs in the first posttransplant

121 been postulated that short wait time before liver transplant (LT) for hepatocellular carcinoma (HCC)

122 The effectiveness of liver transplant (LT) in human immunodeficiency virus (H

123 ion, has been associated with increased post-liver transplant (LT) mortality.

124 tes along with minimal adverse events in non-liver transplant (LT) patients with hepatitis C virus (H

125 This study is a retrospective review of liver transplant (LT) recipients to determine the impact

126 tween January 2007 and December 2011, 12,445 liver transplant (LT) recipients were identified and div

127 irologic response (SVR) improves survival in liver transplant (LT) recipients, and is especially rele

128 hepatitis C virus (HCV) disease severity in liver transplant (LT) recipients.

129 The non-improvement in >1-year post-liver transplant (LT) survival and diminishing importanc

130 ated liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surg

131 However, liver transplant (LT) tolerance absolutely requires inte

132 We analyzed trends in liver transplant (LT) wait-listing (WL) to explore poten

133 d risk of 1-year mortality while receiving a liver transplant (LT), and having localized tumor stage

134 Liver transplant (LT), kidney transplant (KT), and dual

135 umor phenotype and inferior outcomes after a liver transplant (LT).

136 tients with hepatitis C virus (HCV) awaiting liver transplant (LT).

137 n emergent microorganism of infections after liver transplant (LT).

138 antimicrobial prophylaxis is administered to liver transplant (LTx) recipients to prevent surgical si

139 ught to develop a "Model Of Recurrence After Liver transplant" (MORAL) for hepatocellular carcinoma (

140 se of HIV-coinfection (N = 6) or status post liver transplant (N = 2).

141 ati in individuals with a kidney (n = 35) or liver transplant (n = 36).

142 liary strictures (N = 112) due to orthotopic liver transplant (n = 73), chronic pancreatitis (n = 35)

143 unctions in equations to score the risk of a liver transplant or liver-related death occurring within

144 Multivariate predictors of DC included prior liver transplant or major abdominal operation, longer pr

145 ic decompensation, hepatocellular carcinoma, liver transplant, or increase in Child-Turcotte-Pugh sco

146 ngenital cardiac defects, who have undergone liver transplants, or who have acute lymphoblastic leuke

147 al mechanisms by which these cells influence liver transplant outcome.

148 premortem heparin administration improve DCD liver transplant outcomes, thus allowing for the most ef

149 simulated population of patients listed for liver transplant over 5 years, using the liver simulated

150 r risk of graft failure compared to non-ODAT liver transplants (P = .008).

151 Data on polymorphisms in liver transplant patients are sparse.

152 man studies focused on microbiota changes in liver transplant patients are warranted and expected.

153 Antifungal prophylaxis is rational for liver transplant patients at high IFI risk.

154 o standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI.

155 nt trials of immunosuppression withdrawal in liver transplant patients have identified NK cell featur

156 clinical outcomes and renal function in 170 liver transplant patients on cyclosporin A (CsA) or tacr

157 e percentage of Foxp3+ regulatory T cells in liver transplant patients was stable in the study period

158 tive, multicenter, open-label study, de novo liver transplant patients were randomized at day 30 to (

159 A total of 218 consecutive liver transplant patients were reviewed, and 69 patients

160 ment of modifiable risks in those kidney and liver transplant patients who have survived the first po

161 toring of blood serum RP was performed in 64 liver transplant patients, 59 kidney allotransplantation

162 e for the long-term management of kidney and liver transplant patients, with the aim of improving out

163 activities of daily living in pre- and post-liver transplant patients.

164 and posttransplant infections in a cohort of liver transplant patients.

165 or associated with CPM in up to two of three liver transplanted patients with myelinolysis.

166 ly (17% of world activity), resulting in 4.4 liver transplants per million people (pmp) per year.

167 f a prospectively maintained database of all liver transplants performed at our institution from 1998

168 ALD and NAFLD account for nearly 30% of liver transplants performed in the United States.

169 Of the 101 238 liver transplants performed, 61 were related to IBDI.

170 w, we examine current practices in the obese liver transplant population, offer recommendations based

171 MELD 25-29, the 25th and 75th percentiles of liver transplant probability were 30% and 67%, respectiv

172 Out of 3449 liver transplant procedures performed, 516(15%) were SLT

173 f the 7 Eurotransplant countries with active liver transplant programs.

174 ilot with carefully selected patients, early liver transplant provided excellent short-term survival,

175 The top liver transplant rates were found in Argentina (10.4 pmp

176 n the UK only 10% of individuals requiring a liver transplant receive one.

177 h only one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bl

178 ity would significantly advance personalized liver transplant recipient care and management of immuno

179 an important one because the benefits to the liver transplant recipient receiving a kidney transplant

180 We describe the case of a liver transplant recipient who presented with an acute f

181 psy-proven regression of liver fibrosis in a liver transplant recipient with cirrhosis after chronic

182 tential interaction of the microbiome in the liver transplant recipient.

183 We included 33,668 HCV+ liver transplant recipients (54.0 +/- 7.7 years old, 74.

184 sted dose in combination with Tac in de novo liver transplant recipients allows CS discontinuation fr

185 ctional, multicenter study that included 344 liver transplant recipients and examined the level of gl

186 nd actinic keratoses in high-risk kidney and liver transplant recipients and to assess associated fac

187 ver transplantation and the implications for liver transplant recipients are not well understood and

188 Pediatric liver transplant recipients arguably have the most to ga

189 ble-blind trial of antifungal prophylaxis in liver transplant recipients at risk for invasive fungal

190 xpression in liver tissue and serum of adult liver transplant recipients before, early, and late afte

191 l, data were collected from 1799 consecutive liver transplant recipients between January 1, 2002, and

192 Perioperative renal dysfunction in liver transplant recipients complicates maintenance immu

193 iRNA) profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Toler

194 d graft survival was significantly worse for liver transplant recipients from donors with ITP compare

195 ecipients from donors with ITP compared with liver transplant recipients from donors without ITP (64%

196 The prevalence of alcohol use among Finnish liver transplant recipients has not been studied before.

197 Centers with >30% of their liver transplant recipients hospitalized >/=30 days in t

198 Operationally tolerant pediatric liver transplant recipients maintain generally stable al

199 s little is known about the opinion of Dutch liver transplant recipients on anonymity of organ donati

200 Sixty-four percent of liver transplant recipients overall experience a decreas

201 In the United States, 5% of adult liver transplant recipients receive a graft donation aft

202 galactomannan (GM) and beta-D-glucan (BG) in liver transplant recipients remains uncertain.

203 nt randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus

204 ized multicenter open-label trial in de novo liver transplant recipients to assess the feasibility an

205 Despite this, the long-term outcomes of HCV+ liver transplant recipients transplanted from HCV+ donor

206 Our aim is to evaluate long-term outcomes in liver transplant recipients transplanted with HCV antibo

207 tcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monot

208 le-center study of 137 consecutive pediatric liver transplant recipients was to examine the effect of

209 Cadaveric liver transplant recipients were enrolled from January 2

210 Thirty consecutive liver transplant recipients were enrolled in this prospe

211 kidney transplant recipients and 20 cases in liver transplant recipients were included.

212 Adult liver transplant recipients were randomized on the day o

213 In this clinical trial, 129 liver transplant recipients were randomized to be monito

214 A total of 2050 liver transplant recipients were studied, of these 960 (

215 single-center retrospective analysis of 207 liver transplant recipients who achieved MELD score of 4

216 In conclusion, pediatric liver transplant recipients who undergo transfer to the

217 OS did not differ between liver transplant recipients who were not pretreated or p

218 and quantified the circulating ApoL1 in two liver transplant recipients whose native APOL1 genotype

219 are leading causes of long-term mortality in liver transplant recipients with ALD or NAFLD.

220 stochemical analyses of kidney biopsies from liver transplant recipients with chronic CsA nephrotoxic

221 C57BL/6 J wild type and Nox2-/- mice, and in liver transplant recipients with chronic CsA nephrotoxic

222 large report of DC as a viable strategy for liver transplant recipients with coagulopathy or hemodyn

223 ciated conditions that are being provided to liver transplant recipients with diabetes have not yet b

224 th a short course (in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 I

225 ransplantation survival of adult, first-time liver transplant recipients with HCC (n = 9135) or witho

226 ecipients (1995-2013), we selected all adult liver transplant recipients with HCV, and cross-sectiona

227 A retrospective review of adult liver transplant recipients with hepatitis C receiving b

228 nt trend toward the use of elderly donors in liver transplant recipients with low model of end-stage

229 Liver transplant recipients with NASH have a higher risk

230 novo post-transplant type 2 diabetes (DM) in liver transplant recipients with NASH.

231 However, most liver transplant recipients would like to receive some g

232 ients (715 kidney transplant recipients, 190 liver transplant recipients, 102 lung transplant recipie

233 nd graft survival between obese and nonobese liver transplant recipients, but obesity presents import

234 Among young first isolated liver transplant recipients, graft failure risks are hig

235 Few data exist in liver transplant recipients, in whom exercise should be

236 romboembolic events across a wide variety of liver transplant recipients, including those at low risk

237 Among liver transplant recipients, only two of 20 patients rec

238 ong-term treatment with ribavirin is safe in liver transplant recipients, without achieving HEV susta

239 opment of BCs in a large cohort of pediatric liver transplant recipients.

240 crolimus (Advagraf) initiation in kidney and liver transplant recipients.

241 nown whether a similar association exists in liver transplant recipients.

242 ransplant recipients and 10%, 9%, and 13% in liver transplant recipients.

243 uracy for the diagnosis of IFIs in high-risk liver transplant recipients.

244 ed with increased morbidity and mortality in liver transplant recipients.

245 to isoniazid for tuberculosis prophylaxis in liver transplant recipients.

246 A cross-sectional study was conducted in 244 liver transplant recipients.

247 treatment of CMV disease, particularly among liver transplant recipients.

248 h rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype

249 merase inhibitor dasabuvir, and ribavirin in liver-transplant recipients with recurrent HCV genotype

250 -Meier analyses were performed on first-time liver transplant registrants (n = 13 979) and recipients

251 We aimed to describe trends in age among liver transplant registrants and recipients and the effe

252 Dramatic aging of liver transplant registrants and recipients occurred fro

253 Between 2002 and 2014, the mean age of liver transplant registrants increased from 51.2 to 55.7

254 ecipient data were collected from the Nordic Liver Transplant Registry and medical records.

255 his retrospective analysis based on European Liver Transplant Registry comprised data of 73 recipient

256 ecipients with HEHE recorded in the European Liver Transplant Registry during the period November 198

257 Data came from the Nordic Liver-Transplant Registry and WHO mortality-indicator da

258 may confer susceptibility to multiple acute liver transplant rejections in the German population.

259 ue incidence of cardiovascular outcomes post-liver transplant remains unknown in large part due to la

260 and 65% of all individuals with a kidney or liver transplant, respectively, reported an adverse even

261 exists on the treatment of genotype-4 in the liver transplant setting.

262 These International Liver Transplant Society diagnostic and management guide

263 writing group, endorsed by the International Liver Transplant Society, was convened to write guidelin

264 015 and is composed of 20 leading kidney and liver transplant specialists from 9 countries across Eur

265 e immunosuppressive regimen introduced after liver transplant (substudy 2).

266 th an ejection fraction less than 50% during liver transplant surgery.

267 F) is a rare but often fatal complication of liver transplant surgery.

268 There are more than 160 active liver transplant teams in Latin America, but only 30 cen

269 For clinicians caring for patients requiring liver transplant, the key question relates to the timing

270 r survival benefit was achieved by providing liver transplants to patients with HCC (0.12 years/patie

271 ic acute liver failure who did not receive a liver transplant, use of continuous renal replacement th

272 function were observed in individuals with a liver transplant using the Tukey honest significant diff

273 cranial pressure monitored patients received liver transplant (vs 18% controls; p < 0.001).

274 The reduction of liver transplant wait list mortality remains a priority

275 ospective cohort study of children on the US liver transplant wait-list from 2007 through 2014 using

276 & AIMS: Approximately 10% of children on the liver transplant wait-list in the United States die ever

277 Anticipating the future of liver transplant waitlist characteristics is vital when

278 , we found the proportion of patients on the liver transplant waitlist or undergoing liver transplant

279 Among patients new to the liver transplant waitlist or undergoing liver transplant

280 Network registry from 2004 through 2013, on liver transplant waitlist registrants with hepatitis C v

281 NASH became the second-leading disease among liver transplant waitlist registrants, after HCV.

282 The liver transplant waitlist size will remain static over t

283 ring revealed that among patients new to the liver transplant waitlist, or undergoing liver transplan

284 y lead to increased risk of dropout from the liver transplant waitlist.

285 none have focused on the effects of NASH on liver transplant waitlists in the United States.

286 Median waiting time for an elective liver transplant was 4,4 months in 2015; high urgency st

287 5-, and 10-year disease-free survival after liver transplant was 93%, 82%, and 82%, respectively, fo

288 Recipients of 274 living donor liver transplant were enrolled in the Adult-to-Adult Liv

289 varices, ascites, or portal hypertension) or liver transplant were estimated over 1, 2, or 5 years by

290 n, number of primary tumors, tumor size, and liver transplant were independently associated with mort

291 600 HIV-infected patients who had undergone liver transplant were retransplanted.

292 However, because patients with HCC received liver transplants when they had a lower mean MELD score

293 By examining liver transplants where donors and recipients are HLA mi

294 ollow-up of patients on the waiting list for liver transplants who subsequently received a transplant

295 th hepatocellular carcinoma (HCC) listed for liver transplant with tumors just outside stage T2 size

296 tabase identified 12,958 patients listed for liver transplants with HCC exception points from 2006 to

297 eived a kidney transplant and 28% received a liver transplant, with 45% of recipients presenting with

298 813 patients, 150 (8.3%) underwent DC during liver transplant, with 84 (56.0%) requiring a single add

299 We compared patients who received liver transplants, with and without HCC, with regard to

300 The subsequent 6 liver transplants, with livers perfused at lower oxygen